Use of glucosidase inhibitors for therapy of mucovisidosis

Details Use of glucosidase inhibitors for therapy of mucovisidosis Use of glucosidase inhibitors for therapy of mucovisidosis

2011-07-05

2011-07-05

Anderson, James (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S851000

Reexamination Certificate

active

07973054

ABSTRACT:
A method provides for the use of glycosidase inhibitors selected from compounds of general formula (1), wherein R1represents a CH3group, or CH2OH, R2represents H or an alkyl group having 1-5 carbon atoms, or R1and R2together form a group having formula (II), with carbon in position (a) and nitrogen of formula (I) mentioned above, for the preparation of a medicament used to treat mucovisidosis. A corresponding product is also described.

REFERENCES:
patent: 4639436 (1987-01-01), Junge et al.
patent: 6200958 (2001-03-01), Odaka et al.
patent: 2002/0035072 (2002-03-01), Asano et al.
patent: 2004/0081711 (2004-04-01), Rao et al.
patent: 2004/0171674 (2004-09-01), Rao et al.
patent: WO 98/20123 (1998-05-01), None
patent: WO 01/02586 (2001-01-01), None
patent: WO 01/02862 (2001-01-01), None
patent: WO 01/21769 (2001-03-01), None
patent: WO03/037265 (2003-05-01), None
patent: WO 2004/069190 (2004-08-01), None
Dwek et al., “Targeting Glycosylation as a Therapeutic Approach”, Jan. 2002, Nature Reviews Drug Discovery, vol. 1, pp. 65-75.
Andersson et al., “Activation of CFTR by Genistein in Human Airway Epithelial Cell Lines,” Biochemical and Biophysical Research Communications, vol. 308, No. 3, pp. 518-522, Aug. 29, 2003.
Asano (Reprint), “Glycosidase inhibitors: update and perspectives on practical use,” Glycobiology, vol. 13, No. 10. pp. 93R-104R, Publisher: Oxford Univ Press Inc, Journals Dept, 2001 Evans Road, Cary, NC, Oct. 1 2003.
Wei Xiaofang et al: “Turnover of the cystic fibrosis transmembrane conductance regulator (CFTR): Slow degradation of wild-type and DELTA-F508 CFTR in surface membrane preparations of immortalized airway epithelial cells,” Journal of Cellular Phsiology, vol. 168, No. 2, pp. 373-384.
Riddle, MC, Am. Fam. Physician (1999), 60(9), 2613-20.
Ganan, S., et al., “A Major Proportion of N-Glycoprotiens are Transiently Glucosylated in the Endoplasmic Reticulum”, Biochemistry, 1991, pp. 3098-3104, vol. 30, No. 12.
Karlsson, G., et al., “Effects of the Imino Sugar N-Butyldeoxynojirimycin on the N-Glycosylation of Recombinant gp120”, Journal of Biological Chemistry, 1993, pp. 570-576, vol. 268, No. 1.
Trombetta, S., et al., “Purification to Apparent Homogeneity and Partial Characterization of Rat Liver UDP-Glucose:Glycoprotein Glucosyltransferase”, Journal of Biochemistry, 1992, pp. 9236-9240, vol. 267, No. 13.
Platt, F., et al., “N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not Affect N-Linked Oligosaccharide Processing”, Journal of Biological Chemistry, 1994, pp. 27108-27114, vol. 269, No. 43.

Affiliated with

Also associated with

Rating

Use of glucosidase inhibitors for therapy of mucovisidosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of glucosidase inhibitors for therapy of mucovisidosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of glucosidase inhibitors for therapy of mucovisidosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2708183